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Increased connexin43 expression in human saphenous 
veins in culture is associated with intima! hyperplasia 
L'augmentation de 1' expression de la Connexine43 est 
associée à ! 'hyperplasie intimale dans les veines 
saphènes humaines en culture 
Objectif: L'hyperplasie intimale est un processus de remodelage vasculaire qui apparaît après 
une lésion vasculaire. Les mécanismes impliqués dans l'hyperplasie intimale sont la 
prolifération, la dédifférentiation et la migration des cellules musculaires lisses depuis la 
média vers l'espace sous-intimai. Nous avons émis l'hypothèse que les jonctions 
communicantes de type gap, qui coordonnent certains processus physiologiques tels que la 
croissance et la différentiation cellulaire, pouvaient participer au développement de 
l'hyperplasie intimale. 
Méthodes : Des segments de veines saphènes humaines prélevées chirurgicalement lors de 
pontages, ont été ouverts longitudinalement avec la surface luminale placée vers le haut et 
maintenus en culture pendant 14 jours. Des fragments veineux ont été préparés pour une 
évaluation histologique, pour des mesures de l'épaisseur de la néointima, et pour des analyses 
immunocytochimiques de I 'ARN messager ainsi que des protéines. 
Résultats: Parmi les 4 connexines (Cxs 37, 40, 43 et 45) qui forment les jonctions 
communicantes dans les veines, nous avons focalisé notre étude sur l'expression des Cxs 43 et 
40; nous avons démontré que la Cx43 est exprimée dans les cellules musculaires lisses et les 
cellules endothéliales alors que la Cx40 est uniquement présente dans l'endothélium. Après 
14 jours en culture, des analyses histomorphométriques ont montré une augmentation 
significative de l'épaisseur de l'intima démontrant la présence d'hyperplasie intimale. Une 
analyse temporelle a révélé une augmentation progressive de la Cx43 jusqu'à une 
augmentation maximale de six à huit fois au niveau de I' ARN messager et des protéines après 
14 jours en culture. Au contraire, l'expression de la Cx40 n'était pas modifiée. Des analyses 
par immunofluorescence ont montré également une augmentation de la Cx43 dans les 
membranes des cellules musculaires lisses de la média. Le développement de l'hyperplasie 
intimale in vitro est diminué en présence de fluvastatin et cette diminution est associée à une 
réduction de l'expression de la Cx43. 
Conclusions : Ces données démontrent que la Cx43 est augmentée in vitro pendant le 
processus d'hyperplasie intimale et que la fluvastatin prévient cette induction. Ces résultats 
suggèrent un rôle crucial joué par la communication intercellulaire impliquant la Cx43 dans la 
veine humaine durant le développement de l'hyperplasie intimale. 
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Objective: Intimai hyperplasia is a vascular remodelling process that occurs after a vascular injury. The mechanisms 
involved in intimai hyperplasia are proliferation, dedifferentiation, and migration of medial smooth muscle cells towards 
the subintimal space. We postulated that gap junctions, which coordinate physiologie processes such as cell growth and 
differentiation, might participate in the development of intimai hyperplasia. Connexin43 ( Cx43) expression levels may be 
altered in intimai hyperplasia, and we therefore evaluated the regulated expression of Cx43 in human saphenous veins in 
culture in the presence or not of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. 
Methods: Segments ofharvested human saphenous veins, obtained at the time ofbypass graft, were opened longitudinally 
with the luminal surface uppermost and maintained in culture for 14 days. Vein fragments were then processed for 
histologie examination, neointimal thickness measurements, immunocytochemistry, RNA, and proteins analysis. 
Results: Of the four connexins (Cx37, 40, 43, and 45), we focused on Cx43 and Cx40, which we found by real-time 
polymerase chain reaction to be expressed in the saphenous vein because they are the predominant connexins expressed by 
smooth muscle cells and endothelial cells. After 14 days of culture, histomorphometric analysis showed a significant 
increase in the intimai thickness as observed during the process of intimai hyperplasia. A time-course analysis revealed a 
progressive upregulation of Cx43 to reach a maximal increase of sixfold to eightfold at both transcript and protein levels 
after 14 days in culture. In contrast, the expression of Cx40, abundantly expressed in the endothelial cells, was not altered. 
I111111unofluorescence showed a large increase in Cx43 within smooth muscle cell membranes of the media layer. The 
development of intimai hyperplasia in vitro was decreased in presence of fluvastatin and was associated wit11 reduced Cx43 
expression. 
Conclnsions: These data show tliat Cx43 is increased in vitro during the process of intimai hyperplasia and that fluvastatin 
could prevent this induction, supporting a critical role for Cx43-mediated gap-junctional conununication in the human 
vein during t11e development of intimai hyperplasia. (J Vase Surg 2005;41:1043-52.) 
Clinicat Relevance: Stenosis due to intimai hyperplasia is t11e most common cause of failure of verrous bypass grafts. To 
better understand the development of intimai hyperplasia, we used an ex vivo organ culture mode! to study saphenous 
veins harvested from patients undergoing a lower limb bypass surgery. In this mode!, the morphologie and functional 
integrity of the vesse! wall is maintained and significant intimai hyperplasia development occurs after 14 days in culture. 
We have postulated tl1at gap junctions, which coordinate physiologie processes such as cell growtli and differentiation, 
may participate in the development of intimai hyperplasia. Indeed, intimai hyperplasia consists of proliferation and 
migration of smootli muscle cells into the subendothelial space. Intercellular co111111unication is responsible for the direct 
transfer of ions and small molecules from one cell to the other through gap-junction channels found at cell-cell 
appositions. No study to date has evaluated whether gap junctional communication is involved in the process of intimai 
hyperplasia in humans. This assertion was investigated by using the aforementioned organ culture mode! of intimai 
hyperplasia in human saphenous veins, and our data support a critical role for Cx43-mediated gap junctional co111111u-
nication in human vein during t11e development of intimai hyperplasia. 
Stenosis in venons bypass grafts corresponding to inti-
mai hyperplasia is a vascular pathophysiologic feature that 
From the Department ofThoracic and Vascular Surgery,' and the Depart-
ment of Internai Medicine,b University Hospital. 
Supported by grants from the Swiss National Science Foundation ( 31-
068036.02 to J.-A.H, 32-66892.01 to G.W), the Juvenile Diabetes 
Research Foundation (Grant 1-2001-555), and the Placide Nicod, the 
Octav and Marcella Botnar Foundations to G.W and J.-A.H. 
Competition ofinterest: none. 
Reprint requests: J.-A. Haefliger, PhD, PD-MER, Department of Internai 
Medicine, Laboratmy of Molecular Biology 19-135S, University Hospital, 
CHUV-1011 Lausanne, S"1tzerland (e-mail: jhaeflig@chuv.hospvd.ch). 
0741-5214/$30.00 
Copyright© 2005 by The Society for Vascular Surgety. 
doi:l0.1016/j.jvs.2005.02.036 
may result in occlusion of the vesse! lumen. 1-2 Graft wall 
remodelling is caused by adaptation of the vein to extrinsic 
factors such as modified shear stress," wall tension, 3 endo-
thelial damage,4 and platelet activation. 5 -7 Intrinsic prop-
erties of endothelial cells and media! smooth muscle cells 
are also involved in intimai hyperplasia development by 
secreting factors such as platelet-derived growth factor,"- 7 
fibroblast growth factor,R and insulin-like growth factor. 4 
These different factors are implicated in proliferation and 
migration of media! smooth muscle cells into the subinti-
mal space and are associated with a phenotypic modifica-
tion of smooth muscle cells. From a quiescent contractile 
state, the activated smooth muscle cells become prolifera-
1043 
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cive and synthetic.9 •10 Thus, smooth muscle cells produce 
extracellular matrix that composes 80% of the typical IH 
lesion; smooth muscle cells compose the remaining 20%. 
Autologous saphenous vein grafts remain the conduit 
of choice for aortocorona1y and peripheral bypasses, with a 
patency rate of nearly 60% at 10 years. 11 The limited 
patency rate of these vascular procedures is due to intimai 
hyperplasia development, which leads to late graft occlu-
sion. 12 Thus, improvement of the patency rates of these 
procedures by inhibition of neointimal thickening is a 
major goal in vascular research. To understand the devel-
opment of intimai hyperplasia, diftèrent organ culture 
models of human saphenous vein have been proposed. 13 - 16 
We have recently developed an ex vivo setting designed for 
intimal hyperplasia development that uses native human 
saphenous vein segments. In this model, the morphologie 
and functional integrity of the vessel wall is maintained, and 
significant intimai hyperplasia development occurs after 14 
days in culture. 13 ·i+,l 7 -21 
Intercellular communication is responsible for the di-
rect transfer ofions and small molecules from one cell to the 
other through gap-junction channels found at cell-cell ap-
positions.22 Molecular cloning studies have shown that gap 
junctions are formed by members of a family of transmem-
brane proteins named connexins22 that are involved in 
coordinating the electrical and metabolic responses ofhet-
erogeneous cells. 
In the vascular wall, gap junctions show a distribution 
in structures that link ail of the different cell types. 23 
Gap-junction proteins may also coordinate the mechanical 
contractions of smooth muscle cells to modula te the vaso-
motor tone of the vesse! wall. Vasoconstriction and vasodi-
lation waves travel rapidly along the vessel network because 
of the conduction through gap junctions of signais between 
endothelial or smooth muscle cells (or both). 24 
Vascular cell gap junctions are essentially composed of 
four connexins ( Cxs 37, 40, 43, and 45) in various relative 
amounts, depending on species and vascular beds.20 -27 
This mechanism of intercellular communication has a key 
role in a variety ofvascular functions22 •23 and pathologies 
where proliferation and migration are important, such as 
atherosclerosis, 28 endothelial wound repair, 29 and regula-
tion of angiogenesis. 30 
The 3-hydroxy-3-methylglutatyl-coenzyme A (HMG-
CoA) reductase inhibitors (statins) are a class of cholester-
ol-lowering drugs that are used for the prevention and treat-
ment of atherosclerosis. 31 In vitro studies have 
demonstrated tliat statins inhibit the proliferation and mi-
gration of rat smooth muscle cells32 and decreased the 
neointima formation in organ-cultured human saphenous 
vein in association with reduced matrix metalloproteinase-9 
levels. 1831 Recently, statins have been shown to reduce 
Cx43 expression in human vascular cells. 28 
No study to date has evaluated whether gap-junctional 
communication is involved in tl1e process of intimai hyper-
plasia in human. This assertion was investigated by using 
the aforementioned organ culture model of intimai hyper-
plasia in human saphenous veins. Here, we show that the 
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development of intimal hyperplasia was associated with 
changes in the expression of Cx43. 
MATERIALAND METHODS 
Harvesting of human saphenous vein and vein 
culture. Our institutional review committee approved the 
study. Surplus 5-cm-long segments of nonvaricose saphe-
nous vein were obtained from 20 patients (mean patient 
age, 60 ± 3 years; 20 men) undergoing a lower limb bypass 
surgety. The surplus saphenous veins were dissected by 
using a minimal touch technique and those used for tl1e 
experiment were immediately stored in Krebs solution 
without calcium (in mmol/L: NaCI, 118; KCI, 4.7; 
MgS04 , 1.2; IŒP04 , 1.2; NaHC03 , 25; ethylenediami-
netetraacetic acid [EDTA], 0.026; glucose, 11.1). Two-
centimeter segments of the harvested veins were eut open 
longitudinally witl1 luminal surface facing upwards. The 
segments were then pinned out onto a Mersilene mesh 
(Ethicon) in a Pyrex dish, containing a layer ofSylgard 184 
resin (Dow Corning, Seneffe, Belgium) and were cultured 
at 37°C in a humidified atmosphere of95% air, 5% carbon 
dioxide. The segments were immersed in about 5 mL of the 
culture medium (Medium 199 Earle; Biochrom KG) sup-
plemented with 10% newborn calfserum (Gibco BRL) and 
1 % antibiotic-antimycotic solution ( 10,000 U /mL penicil-
lin G, 10,000 U/mL streptomycin sulphate, 25 µg/mL 
amphotericin B, and 5 µg/mL gentamicin) (Gibco BRL). 
The medium was changed every 2 days for 14 days. 13• 14 
The segments were then rinsed with phosphate-buftèred 
saline (PBS) and snap frozen. Fluvastatin (Novartis) was 
used at a target molarity of 1 µM. 
Histologie and histomorphometric analysis. Three 
5-mm segments of vein were harvested before and after 
culture. After fixation in 4% formalin, the vein segments 
were paraffin embedded and 5-µm-thick sections were 
analyzed. Hematoxylin and eosin staining was used for 
histologie analysis, and van Gieson-elastin staining was used 
for histomorphometric assessment. For histomorphom-
etry, the images were first digitalized and histomorphomet-
ric measurements were performed with specially designed 
software (KS 400, Zeiss, Germany) using a standardized 
protocol: 24 measurements of the intimai and media! thick-
ness, evenly distributed across the whole section, were 
processed on each of two consecutive sections of each 
segment at a magnification of X25. 
RNA isolation and polymerase chain reaction. 
Fragments of the human saphenous vein were homoge-
nized in the Tripure Isolation Reagent (Roche Diagnostics, 
Switzerland) using a Kinametic Polytron blender 
(Kinametica, Switzerland), and total RNA was extracted 
using the kit procedure. For real-time polymerase chain 
reaction (RT-PCR), total RNA was treated for 30 minutes 
in the presence ofDNase I (DNA-free kit, Ambion, Cam-
bridge, UK) and reverse-transcribed using ImProm-II Re-
verse Transcription System (Promega, Switzerland). The 
PCR reaction was performed in the presence of 20 ng 
sense- and antisense-specific primers using recombinant 
Taq DNA polymerase (Gibco-BRL). 
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The products obtained after 30 PCR cycles performed 
in a PCRmachine (Biometra, Switzerland) with the differ-
ent primers were visualized after ethidium bromide staining 
on agarose gel. Negative controls included amplification of 
distilled water and human vein RNA samples that had not 
been reverse-transcribed. The following primers were used: 
• human Cx43 (649 bp fragment): 5'-GAACTCAAG-
GTTGCCCAAAC-3' (sense primer) and 5'-TTA-
GAGATGGTGCTTCCCG-3' (antisense primer); 
• human Cx40 (416 bp fragment): 5'-TGGAGGT-
GGGCTTCATTGTG-3' (sense primer) and 5'-
TACTTGCTCGGTGACCAGGTTG-3' ( antisense 
primer); 
• human Cx37 (718 bp fragment): 5'-ACGAGCAGT-
CAGATTTCG-3' (sense primer) and 5'-GGATGA-
GAGCCCATTGTAG-3' (antisense primer); 
• human Cx45 (570 bp fragment): 5'-GATTGC-
CAAAATGGAGCACG-3' (sense primer) and 5'-
AGGGGGAGCAGATGGTGTA TTC-3' ( antisense 
primer); and 
• human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (114bp): 5'-AACTTTGGTATCGTG-
GAAGG-3' (sense primer), and 5'-CAGTAGAGG-
CAGGGATGATGT-3' (antisense primer). 
Quantitative RT-PCR was performed on total RNA 
treated 30 minutes in the presence ofDNase 1 (DNA-free 
kit, Ambion, Cambridge, UK) by using a LightCycler 
instrument (Roche Diagnostics GmBbH, Mannheim, Ger-
many) and the QuantiTect SYBR Green PCR Kit ( Qiagen, 
Base!, Switzerland). One-microgram aliquots of DNase-
treated RNA were reverse-transcribed using ImProm-11 
Reverse Transcription System (Promega), as described in 
the kit protocol. The cDNA samples were subjected to 
serial dilutions in water. Each reaction mixture (20 µL) 
contained 4 µL cDNA, lOµL 2X PCRMaster Mix (con-
taining HotStarTaq DNA Polymerase, buffer, and dNTPs) 
and 3 pmol of each primer. 
The amplification pro gram consisted of one cycle of 15 
minutes at 95°C, followed by 45 cycles of 15 seconds at 
95°C, 20 seconds at 50° to 52°C, and 20 seconds at 72°C. 
In each run, contamination and specificity of the PCR was 
checked by including both a nonreverse-transcribed RNA 
sample and a sample of 2X PCR master mix containing 3 
pmol of each primer, respectively. Amplification was fol-
lowed by melting curve analysis to verify the identity of the 
amplicon. 
PCR efficiency was determined by analyzing a dilution 
series of the RT-PCR reaction that contained the target 
gene and that served as a reference standard. Analysis of 
data was performed using the 3.5 version of the Light 
Cycler software (Roche Diagnostics GmbH, Germany), 
which generated a best-fit line from the log-linear region of 
each curve defining the crossing line. The intersection 
between the emitted fluorescence and the crossing line 
defined the crossing point. The concentration of target 
DNA was calculated by plotting the crossing point of each 
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sample on the standard curves. The cDNA was amplified 
using the following primers: 
• human Cx43 (123 bp): 5'-TTTCAATGGCTGCTC-
CTC-3' (sense primer) and 5'-TGCTCACTTGCTT-
GCTTGTT-3' (antisense primer); 
• humanf32 microglobulin(100bp): 5'-TGAGTATGC-
CTGCCGTGTGA-3' (sense primer) and 5'-
GGCATCTTCAAACCTCCATG-3' (antisense prim-
er); and 
• human GAPDH ( 114bp ): 5 '-AACTTTGGTATCGTG-
GAAGG-3' (sense primer) and 5'-CAGTAGAGG-
CAGGGATGATGT-3' (antisense primer). 
Data were analyzed with the LightCycler Software 
(Roche, Roche Diagnostics). 
Western blotting. Fragments of human saphenous 
vein were rapidly frozen in liquid nitrogen. Each vein was 
pulverized with a pestle and mortar precooled in liquid 
nitrogen, and the powder was homogenized and sonicated 
in 62.5 mM Tris(hydroxymethyl)aminomethane (pH 6.8), 
5% sodium dodecylsulfate, and 10 mM EDTA. Protein 
content was determined by Bio-Rad DC Protein Assay 
Reagent Kit (Bio-Rad Laboratories). 
Aliquots ofveins were heated at 50°C in loading buffer, 
fractionated by electrophoresis in a 12.5% polyacrylamide 
gel, and immunoblotted overnight onto lmmobilon poly-
vinylidene fluoride membranes (Millipore Co) at a constant 
20V. Membranes were incubated for 1 hour in PBS con-
taining 5% milk and 0.1% Tween 20 and then incubated 
overnight at 4°C with an antiserum against Cx43 (antirab-
bit polyclonal antibodies, AB1728, Chemicon) or Cx40 
(antirabbit poyclonal antibodies, AB1726, Chemicon) di-
luted 1 :200, tubulin, or 13-actin antihuman smooth muscle 
cells (Sigma, St Louis, Mo) diluted 1 :2000 in blocldng 
buffer. 
After the immunoblots were rinsed in PBS containing 
0.1% Tween 20, they were incubated for 1 hour with 
anti-rabbit immunoglobulin (Ig) antibody coupled to alka-
line phosphatase (Dako Diagnostic AG) that was diluted 
1:5000. Antigen-antibody complexes were detected with 
the HRP Western blot detection system (Amersham). In 
these experiments, controls included use of rat lungs and 
bovine aorta endothelium. 
lmmunofluorescence and histochemistry. The hu-
man saphenous veins were eut in fragments that were 
quickly frozen in 2-methylbutane precooled in liquid nitro-
gen. Vein fragments were frozen in optimal cutting tempera-
ture medium (Miles Inc) and cryo-sectioned at about 5 µm 
tluckness. Sections were rinsed in PBS, incubated 30 min-
utes in a buffer containing 0.5% bovine serum albumin 
(BSA) and 0.2% Triton X-100, and then exposed for 20 
hours to antibodies against either Cx43 (AB1728, Chemi-
con), or Cx40 (ABl 726, Chemicon) and a-smooth muscle 
cell actin (A2547, Sigma) diluted 1:500 in PBS. Primary 
antibodies were detected using secondary antibodies la-
belled with fluorescein isothiocyanate (Molecular Probes 
Inc) and directed against rabbit IgG. Sections were then 
rinsed in PBS, counterstained with Evans Blue and cover-
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Fig 1. Upper panel, Development of intimai hyperplasia in lm-
man saphenous vein segments after 14 days in culture. A, Com-
pared with control vein, (B) intima! and subintimal space thick-
ness, corresponding to intimai hyperplasia (IH) is markedly 
increased (van Gieson-elastin staining) in hum an venons segment 
after 14 days in culture. C and D, Immunolabeling of the sections 
shown in A and B, with antibodies against cx-actin (brown color) 
revealed the presence of smooth muscle cell proliferation in the 
neointima (arrows in A, B, C, and D, represent the lamina elastica 
interna). E and F, Immunolabeling with antibodies against the 
factor VIII demonstrated the presence of endothelial cells along 
the vesse!. Original magnification, X400 in A, B, C, D and X200 
for E and F. L, Lumen; J, intima; IH, intimai hyperplasia; M, 
media. Lower panel, Quantitative assessment of six measurements 
(one per human vein segment) of intimai and subintimal space 
thickness, corresponding to intimai hyperplasia, was significantly 
increased in vein segments incubated in culture for 14 days com-
pared with contrais (NatiJ1e); ** P < .01. 
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slipped. Paraffin embedded sections (5 µm) were also im-
munolabeled with antibodies recognizing von Willebrand 
factor (Dako diluted 1: 1000) or the smooth muscle cells 
[3-actin (diluted 1:1000) (A5441, Sigma). Sections were 
viewed on a microscope (Leica). 
Statistical analysis. Data were expressed as mean ::+: 
SEM. Differences bet:ween means were assessed with the 
Student's t test, analysis of variance, or both. Statistical 
significancewas defined ata value of P< .05, P< .01, and 
P< .001. 
RESULTS 
An in vitro model of luunan saphenous vein 
hyperplasia. Intimai hyperplasia was induced experimen-
tally using an ex vivo organ culture mode! ofhuman saphe-
nous veins. Veins were incubated in culture for a period of 
14 days. The integrity of the vesse! wall was maintained 
during the culture period (Fig 1, A and B). The presence of 
smooth muscle cells and endothelial cells was demonstrated 
using immunoreactivity for cx-actin ( expressed in smooth 
muscle cells, fig 1, C and D) and for von Willebrand factor 
( expressed by endothelial cells, Fig l, E and F). Quantita-
tive assessment of histomorphometric measurements from 
van Gieson-elastin stained sections of six different venons 
segments before and after vein culture during a period ofl 4 
days demonstrated a significant increase of the ratio be-
t:ween intimai and media! thickness compared to the respec-
tive freshly isolated vein (Fig l, lower panel). 
lncreased connexin43 in human saphenous vein in 
culture. RT-PCR analysis of freshly isolated human vein 
mRNA demonstrated the presence of a transcript for four 
connexins (Cx37, Cx40, Cx43, and Cx45) but not for 
Cx36 (data not shown). After 14 days in culture, the tran-
script for Cx43 was increased and a similar expression pattern 
was observed for the Cx37, Cx40 and Cx45 mRNAs com-
pared with controls (Fig. 2, A). In view ofprevious reports 
on human33 and rabbit34 vascular smooth muscle cells, we 
focused our experiments on Cx43, thought to be the 
prominent connexin in smooth muscle cells. 
Quantitative RT-PCR evaluation of Cx43 mRNA expres-
sion normalized with [32 microglobulin or GAPDH (not 
shown) in human saphenous vein in culture demonstrated 
that hyperplasia was associated with a large increase in the 
levels of Cx43 mRNA after 14 days in culture (Fig 2, B). 
Western blot analysis of total human vein extracts 
showed that Cx43 was expressed as t:wo major immunore-
active forms, with apparent molecular weights of 43 and 44 
kDa. Comparison of multiple independent sampi es showed 
that the levels of Cx43 were significantly increased in tl1e 
vein after 14 days in culture. Quantitative evaluation of the 
two immunoreactive bands revealed that after 14 days in 
cultüre, the levels of Cx43 were increased (P< .001) about 
eightfold (Fig 2, C and D). The expression of Cx43 rose 
bet:ween 1 and 3 days in culture, and was greatest at 14 days 
(Fig 3 ). Throughout this period, there was no change in the 
levels ofCx40 (Fig 3). 
Immunolabeling demonstrated that Cx43 was immu-
nolocated on smooth muscle cells of freshly frozen human 
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Fig 2. Connexin43 ( Cx43) is increased at both mRNA and protein levels in veins after 14 days in culture. A, Multiple 
connexin transcripts are expressed in the human saphenous vein wall. Reverse-transcribed human saphenous vein RNA 
was amplified by polymerase chain reaction (PCR) using primers specific for human Cx37, Cx40, Cx43, and Cx45. The 
amplification of four amplicons corresponding to Cx37, Cx40, Cx43, and Cx45 are shown after ethidium bromide 
staining. These products were not amplified in samples that were not reverse-transcribed before PCR processing (-). 
This experiment was performed in triplicate with different human vein segments. B, Expression of Cx43 mRNA 
analyzed by quantitative real-time PCR is increased in vein that is developing intima! hyperplasia. Quantitative 
assessment of six to seven measurements (one per human vein segment) showed that Cx43 mRNA was increased sixfold 
in vein segments cultured during a period of 14 days compared with control veins (Nath1e). Values represent ratios 
between Cx43 and [32 -microglobulin mRNAs expression. Data are expressed as mean ±SEM;*** P< .001. GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase. C and D, Western blot analysis of total proteins showed that the levels of 
Cx43 were markedly increased (about 10-fold) in vein after 14 days in culture compared with control levels. Data are 
expressed as mean ± SEM; P < .001. BA, bovine aorta. Under both conditions, Cx43 was detected as two bands of 
43-44 kDa. Each lane represents a sample from a <liftèrent vein. All lanes were loaded with 75 µ,g total proteins. In the 
same samples, levels of tubulin were not modified. As positive control, 25 µ,g of freshly scraped bovine aortic 
endothelium was used. 
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Fig 3. Cx43 protein levels change during the development of 
intimai hyperplasia in human saphenous vein. Western blot analysis 
of total proteins content revealed that the expression of con-
nexin43 (Cx43) in venons samples progressively increased during 
the first 3 days of organ culture. In the same samples, no change in 
the expression of Cx40 was observed during culture period. Ail 
lanes were loaded with 75 µg of total proteins. Bach Jane repre-
sents a sample from a diffèrent vein. As positive controls, 25 µg of 
bovine aorta (BA) endothelial proteins and 40 µg of rat lung (RL) 
proteins were used. Levels of tubulin proteins were not modified. 
saphenous vein (Fig 4 A, upper panel). After 14 days in 
culture, a marked increase in the number of immunoreac-
tive dots was observed in the smooth muscle cells (Fig 4, E 
and G upper panel). Fig 4, C and G (upper panel) also 
showed Cx43 expression on both smooth muscle cells and 
endothelial cells. Cx40 staining was only observed in the 
endothelial layer (Fig 4, H upper panel). 
Immunofluorescence labeling of serial sections of the 
human saphenous vein before (Fig 4, A and B lower panel) 
and after 14 days in culture (Fig 4, C and D lower panel) 
was performed using specific antibodies against Cx43 and 
a-smooth muscle cells. These data revealed that the in-
crease in the number of Cx43 immunofluorescent spots 
observed after 14 days in culture occurs mainly in the 
smooth muscle cells. 
Reduction of intimai hyperplasia and Cx43 expres-
sion in organ culture by fluvastatin. We examined 
whether the cholesterol-lowering drug fluvastatin inhibited 
the neointima formation in organ-cultured human saphe-
nous vein. Fluvastatin reduced neointimal thickness of 
about 50% (P< .01) (Fig 5, A) at a concentration ofl µM 
known to have no detrimental effects on cell viability in 
saphenous vein organ cultures. 18 ' 35 Western blot analysis of 
veins segments cultured for 14 days in presence of fluva-
statin demonstrated a marked decrease in the levels of the 
two immunoreactive bands corresponding to Cx43 (Fig 5, 
B). Cx43 was significantly reduced by 50% to 70% in tl1e 
veins incubated in presence of fluvastatin compared with 
controls (P < .01) (Fig 5, C). 
DISCUSSION 
Stenosis due to intimai hyperplasia is the most common 
cause of failure of venons bypass grafts. To better under-
stand the development of intimai hyperplasia, we used 
saphenous veins harvested from patients undergoing a 
lower limb bypass surgery in an ex vivo organ culture 
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model. This mode! maintains the morphologie and func-
tional integrity of the vesse! wall and a significant develop-
ment of intimai hyperplasia occurs after 14 days in culture. 
We have postulated iliat gap junctions, which coordinate 
physiologie processes such as cell growtl1 and differentiation, 
may participa te in the development of intimai hyperplasia. 
Indeed, intimai hyperplasia consists of proliferation and 
migration of smooth muscle cells into the subendothelial 
space. This is the first study that evaluates the involvement 
of gap junctional communication in the process of intimai 
hyperplasia in humans. Our data demonstrate a critical raie 
for Cx43-mediated gap junctional communication in the 
human vein during the development of intimai hyperplasia 
in the aforementioned organ culture mode!. 
Gap junction channels provide an enclosed conduit for 
direct exchanges of signalling molecules, including ions 
and small metabolites, between cells. This system of 
communication allows cells to review the functional state of 
their neighbors. In vessels, endoilielial cells may express 
three connexin isotypes, namely Cx37, Cx40, and Cx43, 
whereas the underlying smootl1 muscle cells may express 
Cx37, Cx40, Cx43, and Cx45. In most vascular smooth 
muscle cells, Cx43 expression and function seem domi-
nant. 36-38 
Our study investigated the changes in Cx43 expression 
that might accompany the development of intimai hyper-
plasia in an in vitro culture mode! ofhuman saphenous vein. 
We showed that Cx43, but not Cx40, is markedly overex-
pressed during the 14-day culture period in the smooth 
muscle cells and that treatment with fluvastatin caused a 
reduction of neointima formation in cultured human sa-
phenous vein segments in association with a marked de-
crease in Cx43 expression. These results provide evidence 
that increased Cx43 is associated with the in vitro develop-
ment of intimai hyperplasia in the human vein. 
Statins and marimastat have been shown to decrease 
intimai hyperplasia by reducing matrix metalloproteinase-9 
activity and smooth muscle cell proliferation. 17 Recently, it 
has been demonstrated that statins reduced Cx43 expres-
sion in primary human vascular cells in vitro,28 and in vivo 
studies have further shown an association between reduced 
Cx43 expression levels in mice treated with statins and the 
presence of a lower number of inflammatory cells in ather-
oma. 28 Although we used an in vitro organ culture moçlel, 
it uses the exact tissue (saphenous vein) that causes the 
clinical problem in vivo and our observations provide the 
first report that statins reduced Cx43 expression in human 
vascular tissue. 
Communication via gap junctions has been implicated 
in the regulation of cell growth, diftèrentiation39 and mi-
gration.29·30'40-42 These three processes have a central raie 
in the development ofintimal hyperplasia. Accordingly, we 
show that conditions that modify vein homeostasis due to 
changes in the proliferation and migration rate of smooth 
muscle cells are associated with a marked increase in Cx43 
expression. During hyperplasia, the increase of Cx43 is 
associated with smooth muscle ce!! proliferation, and the 
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mechanism underlying the changes in Cx43 expression 
remains to be elucidated. 
The finding that the changes in Cx43 expression took 
place within few days indicates that the increase in Cx43 
expression in smooth muscle cells is an early event. Changes 
in Cx43 levels were also significantly faster than those 
required to observe structural wall modifications, such as 
smooth muscle cells hyperplasia and migration, suggesting 
tl1at alterations of the normal connexin pattern may induce 
the subsequent structural and functional changes in the 
muscle layer. 
The abundance of Cx43 suggests that gap junctional 
communication between smooth muscle cells may play a 
role in the initiation of tl1e proliferative response and su b-
sequently in maintaining it. The response of smooth muscle 
cells in tl1e human vein initially involves replication in the 
media followed by migration to tl1e neointima, and tl1e 
question concerns the relationship between tl1e upregula-
tion of Cx43 and the development of intimai hyperplasia. 
Increasing evidence suggests that reduced gap junctional 
communication is involved in uncontrolled growth.43 -45 
Our findings suggest, however, that upregulation of Cx43 
in tl1e human vein is linked to smooth muscle cell activation 
and may be a transient event in the cell cycle of the smooth 
muscle cell, as has already been observed during vascular 
healing in tl1e rat carotid artery. 46 
Intimai hyperplasia is the process by which the cell 
population increases within the innermost layer of the 
arterial wall47 such as occurs physiologically in ho -
mografts, transplanted organs,48 and in veins used as 
arteriovenous fistulas or arterial bypass grafts .49 It con-
sists of proliferation of the vascular smooth muscle cells 
Fig 4. Connexin43 (Cx43) is increased in smooth muscle cells of 
human saphenous vein in culture. Upper panel, Phase-contrast 
views of sections of human saphenous vein before (B) and after 14 
days in culture (D, F). Immunofluorescence labeling with specific 
antibodies located Cx43 at discrete spots dispersed throughout the 
media of the vein wall (A). A sizable increase in the number and 
pattern of these spots was noticed in human vein that was devel-
oping hyperplasia after 14 days in culture (C, E). The limited 
amount of Cx43 expressed by the endothelial cells is visible in 
panel E. Cx43 expression in smooth muscle located in the intimai 
hyperplasia cells is visible on panel C and G. Immunofluorescence 
labeling with Cx40 antibodies reflected the presence ofCx40 only 
in the endothelial cells (H). L, Lumen; I, intima; IH, intimai 
hyperplasia; M, media. Original magnification: X400. Lower 
panel , Immunofluorescence labeling of serial sections of the hu-
man saphenous vein be fore (A, B) and after 14 days in culture ( C, 
D). Alpha-smooth muscle actin was localized in the smooth mus-
cle cells of the human vein (A, C) and demonstrated that Cx43 is 
located in the human vein smooth muscle cells (Band D). Cx43 
and cx -smooth muscle staining revealed that the increase in the 
number ofCx43 immunofluorescent spots observed after 14 days 
in culture occurred in the smooth muscle cells (B, D). Arrows 
indicate the presence of cx-smooth muscle actin in A and C and 
Cx43 in B and D. L, Lumen; M, media. Original magnification, 
X400. 
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Fig 5. Fluvastatin decreased intimai hyperplasia and connexin43 (Cx43) levels in human saphenous veins in culture. 
A, Quantitative assessment of six measurements (one per human vein segment) of intimai thickness, corresponding to 
intimai hyperplasia, was significantly decreased in vein segments after 14 days in culture in the presence of fluvastatin 
compared with contrai veins cultured without fluvastatin. ** P < .01. B, Western blot revealed that the levels ofCx43 
were decreased in vein segments incubated in the presence of fluvastatin compared with contrais. C, Quantitative 
evaluation of six immunoblots (one per vein) revealed that the levels of Cx43 were decreased threefold to fourfold in 
veins incubated with fluvastatin. ** P < .01. 
followed by their migration across the lamina elastica 
interna and their secretion of extracellular matrix in the 
subendothelial space. 
The contractile smooth muscle cells of adult veins 
exhibit low rates ofproliferation50; they are rarely called 
upon migrate to re-establish vascular integrity, but 
smooth muscle cells retain the ability to migrate and 
<livide rapidly in response to injury. Such a change in 
behavior requires a switch in the spectrum of active genes 
involved for migration and proliferation 51 such as the 
metalloproteinase 31 and the nitric oxide synthase 
genes. 52 The marked increase of Cx43, already observed 
after a few days in cultured veins, suggests that Cx43 
might play a raie in the initiation step of proliferation 
and also during the formation of intimai hyperplasia. 
Atherasclerasis, the most common pathophysiologic 
pracess, involves expansion of the intimai vascular smooth 
muscle cell population53 together with the accumulation of 
lipids and leucocytes. 54 Evidence is grawing that dysfünc-
tional gap junctional intercellular communication is in-
volved in the development of atherasclerasis. 55 Blackburn 
et al 56 reported that Cx43 expression in intimai smooth 
muscle cells was shown to increase at the early stages of 
human coranary atherasclerasis and to decrease at later 
stages of the disease. 56 Recently, it was demonstrated that 
the expression ofCx43, Cx40, and Cx37 is altered in atl1ero-
sclerotic plaques57 and that reduced Cx43 levels inhibit the 
formation of atherosclerotic lesions in low-density-lipoprotein 
receptor-deficient mice. 28 These data indicate that Cx43 has a 
raie in atherosclerotic plaque formation, and a possible mech-
anism may involve Cx43-mediated eftècts on smooth muscle 
cell proliferation or fonction. 55 
To proliferate and migrate, vascular smooth muscle 
cells should undergo a phenotypic transformation, which is 
a key step in neointimal formation. From their resting, 
contractile state, they revert to a more embryonic pheno-
type that allows the synthesis of extracellular matrix. Inhi-
bition of this change by transfonning growth factor-13 
(TGF-13 )58 can prevent the development of intimai hyper-
plasia. It was recently demonstrated that the Cx43-medi-
ated heterocellular gap junction between endothelial and 
mesenchymal cells is necessary for contact-dependent acti-
vation ofTGF-13, which mediates endothelial-induced mu-
ral cell differentiation. 59 These data reinforce the hypothe-
sis that increased Cx43 expression plays a raie in the 
differentiation of smooth muscle cells. 38060061 
In conclusion, our findings represent an important 
contribution to the understanding of the mechanisms 
involved in the development of intimai hyperplasia by 
identifying Cx43 as a target pratein that is markedly 
increased in intimai hyperplasia. These data also show 
that fluvastatin could prevent this induction, supporting 
a crucial raie for Cx43-mediated gap junctional commu-
nication in the human vein during the development of 
intimai hyperplasia. 
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